Search

Axsome Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

207.75 -2.66

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

206.19

Max

213.31

Schlüsselkennzahlen

By Trading Economics

Einkommen

13M

-51M

Verkäufe

27M

218M

EPS

-0.99

Gewinnspanne

-23.498

Angestellte

1,346

EBITDA

11M

-50M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+35.8% upside

Dividenden

By Acuity

Nächstes Ergebnis

2. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

485M

11B

Vorheriger Eröffnungskurs

210.41

Vorheriger Schlusskurs

207.75

Nachrichtenstimmung

By Acuity

7%

93%

2 / 339 Ranking in Healthcare

Axsome Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

18. Sept. 2026, 19:46 UTC

Axsome Therapeutics Inc shares fell after reaching an early high, remaining below Thursday's close and stabilizing around the middle of its one-month trading range.

16. Sept. 2026, 20:10 UTC

Macro Event

Axsome Therapeutics Inc is advancing amid broader market reactions to the Federal Reserve's 25 basis point interest rate hike, consolidating gains above its 20-day moving average.

15. Sept. 2026, 21:01 UTC

Axsome Therapeutics Inc shares are lower in after-market hours, showing unusual volatility and trading below its 20-day moving average. No specific news was identified.

14. Sept. 2026, 20:07 UTC

Social Media

Axsome Therapeutics shares are lower today, continuing a decline since Friday. Recent prescription data and a price target of $316 from Mizuho have not supported the stock.

12. Sept. 2026, 00:01 UTC

Social Media

Axsome Therapeutics shares rise in after-market trading, supported by Mizuho's $316 price target and positive prescription data for Auvelity.

11. Sept. 2026, 20:01 UTC

News
Social Media

Axsome Therapeutics shares rise following positive analyst commentary on Auvelity's launch and strong prescription growth, with unusually high trading volume today.

9. Sept. 2026, 20:07 UTC

Axsome Therapeutics Inc. shares are higher today, continuing a positive trend since Tuesday's close amid typical trading activity within its one-month range.

8. Sept. 2026, 19:36 UTC

Axsome Therapeutics Inc shares are higher today amid routine trading, with no specific company news identified. The stock has gained since Friday's close.

4. Sept. 2026, 22:40 UTC

Axsome Therapeutics Inc. shares are higher in after-market hours, recovering from an earlier pullback and achieving a notable return since Friday's close.

3. Sept. 2026, 20:07 UTC

Axsome Therapeutics Inc shares are trading lower today, with no specific news identified to explain the decline amid a broader market downturn.

2. Sept. 2026, 20:01 UTC

News

Axsome Therapeutics will participate in several upcoming investor conferences, boosting shares amid positive sentiment regarding its outreach efforts.

1. Sept. 2026, 19:51 UTC

Event
News

Axsome Therapeutics Inc. announced the first patient has been dosed in the SUMMIT Phase 3 trial of AXS-05 for smoking cessation, boosting shares higher.

31. Aug. 2026, 21:02 UTC

Event

Axsome Therapeutics shares rise in after-market hours following the dosing of the first patient in the SUMMIT Phase 3 trial for AXS-05.

29. Aug. 2026, 00:01 UTC

Axsome Therapeutics Inc is higher in after-market trading, advancing since Friday's close, though still below its 20-day moving average.

28. Aug. 2026, 23:46 UTC

Axsome Therapeutics Inc shares are higher in after-market hours, though no specific news was identified to explain the movement. They remain below their 20-day moving average.

27. Aug. 2026, 19:36 UTC

Axsome Therapeutics Inc. shares are trading lower, continuing a decline since Wednesday and remaining near the lower end of their one-month trading range.

26. Aug. 2026, 19:36 UTC

Axsome Therapeutics Inc. shares are trading higher today, recovering from an early dip. The stock remains below its 20-day moving average.

25. Aug. 2026, 21:01 UTC

Axsome Therapeutics Inc shares are lower in after-market hours, continuing a trend of four consecutive sessions finishing down and trading below the 20-day moving average.

24. Aug. 2026, 21:01 UTC

Axsome Therapeutics Inc shares are lower in after-market trading. The stock has declined for four consecutive sessions and remains below its 20-day moving average.

21. Aug. 2026, 19:41 UTC

Axsome Therapeutics Inc. shares are lower today, retracing from earlier gains and remaining below the 20-day moving average amid rising Treasury yields.

20. Aug. 2026, 20:01 UTC

Axsome Therapeutics Inc's shares are declining amid broader market pressures from Walmart's disappointing earnings, raising concerns about consumer spending.

17. Aug. 2026, 19:16 UTC

Axsome Therapeutics Inc shares are higher today, continuing an upward trend since Friday's close. No specific news was identified to explain the movement.

14. Aug. 2026, 19:36 UTC

Axsome Therapeutics Inc shares are higher today, rebounding from an earlier pullback, despite a broader market influenced by a decline in retail sales.

13. Aug. 2026, 19:56 UTC

Axsome Therapeutics Inc shares are declining, retracing from earlier session highs amid broader market trends and rising U.S. unemployment claims.

12. Aug. 2026, 22:36 UTC

Axsome Therapeutics shares higher in after-market trading, with no specific news identified. Broader market stability follows recent inflation data easing rate hike concerns.

11. Aug. 2026, 19:45 UTC

Social Media
News

Axsome Therapeutics shares are lower following a second-quarter loss of 99 cents per share, missing the consensus estimate of 83 cents.

10. Aug. 2026, 23:06 UTC

Axsome Therapeutics Inc shares are lower during after-market hours amid mixed market sentiment. The stock is trading below its 20-day moving average.

7. Aug. 2026, 19:52 UTC

Axsome Therapeutics Inc shares are higher during Friday's session, recovering from a brief dip after reaching a session high. No specific news was identified.

6. Aug. 2026, 23:01 UTC

Axsome Therapeutics Inc. is trading higher in after-market hours, showing stability despite no specific news. The stock remains below its 20-day moving average.

5. Aug. 2026, 19:36 UTC

Axsome Therapeutics Inc shares are lower, pulling back from earlier session highs. The stock remains significantly below its 20-day moving average.

Peer-Vergleich

Kursveränderung

Axsome Therapeutics Inc Prognose

Kursziel

By TipRanks

35.8% Vorteil

12-Monats-Prognose

Durchschnitt 291 USD  35.8%

Hoch 380 USD

Tief 251 USD

Basierend auf 13 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Axsome Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

13 ratings

12

Buy

1

Halten

0

Sell

Stimmung

By Acuity

2 / 339 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.